Probiotics for Prevention of Pyrotinib/Neratinib-Induced Diarrhea in Breast Cancer Patients
- Conditions
- HER2-positive Breast CancerDiarrhea Caused by DrugNeratinibPyrotinib
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-05-13
- Target Recruit Count
- 308
- Registration Number
- NCT06892093
- Locations
- 🇨🇳
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
- Conditions
- Breast Cancer Stage IV
- Interventions
- Drug: Camrelizumab+Apatinib+EribulinDrug: Physician's choice chemotherapy
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-05-15
- Target Recruit Count
- 246
- Registration Number
- NCT06889688
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
🇨🇳The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳Wuhan Union Hospital of China, Wuhan, Hubei, China
Comparing the Efficacy of Domestic Versus Imported Hearing Aids in ARHL
- Conditions
- Age-related Hearing LossHearing Loss, Sensorineural
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-19
- Target Recruit Count
- 80
- Registration Number
- NCT06882889
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Clinical Features and Current Treatment of Primary Headache
- Conditions
- Primary Headache
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-19
- Target Recruit Count
- 2000
- Registration Number
- NCT06883955
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary
- Conditions
- Exploring HER2 Positive Diagnostic Criteria in High-grade Serous Ovarian CancerObserving the Effectiveness of Targeted HER2 ADC Drugs
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-19
- Target Recruit Count
- 144
- Registration Number
- NCT06883487
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Methylprednisolone With Endovascular Thrombectomy for Large Ischemic Stroke
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: Methyprednisolone sodium succinateDrug: Placebo
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-11
- Target Recruit Count
- 1614
- Registration Number
- NCT06870448
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
- Conditions
- Metastatic Triple-negative Breast Cancer
- Interventions
- Drug: ADC +anti-angiogenic drugDrug: ADC + PD1 monoclonal antibody +anti-angiogenic drug
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Target Recruit Count
- 60
- Registration Number
- NCT06851299
- Locations
- 🇨🇳
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;, Guangzhou, Guangdong, China
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Carcinoma: A Phase II Study
- Conditions
- Breast Carcinoma in Situ
- Interventions
- Drug: Trastuzumab combined with taxane neoadjuvant therapy
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-02-25
- Target Recruit Count
- 54
- Registration Number
- NCT06843681
An Intelligent Pressure and Temperature Control Ureteral Soft Scope System for Treating Stones With Infection.
- Conditions
- UreterolithiasisRenal Calculi
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-03-07
- Target Recruit Count
- 288
- Registration Number
- NCT06841523
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC
- Conditions
- Advanced HCCTargeted TherapyChemotherapySystemic TherapyImmunotherapyEfficacy and Safety
- Interventions
- Drug: TKIDrug: anti PD-1Drug: XELOX chemotherapy
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-05-20
- Target Recruit Count
- 68
- Registration Number
- NCT06818097
- Locations
- 🇨🇳
Sen Memorial Hospital, Guangzhou, Guangdong, China